EndoGastric Solutions
US-based EGS manufactures EsophyX tech for gastroesophageal valve reconstruction in TIF 2.0 procedures.
Founded
2003US-based EGS manufactures EsophyX tech for gastroesophageal valve reconstruction in TIF 2.0 procedures.
EndoGastric Solutions, founded in Redmond, United States, focuses on developing innovative treatment options for gastroesophageal reflux disease (GERD). The company's core mission is to improve the quality of life for GERD patients by providing less invasive, more effective solutions. Their flagship product, EsophyX, is used in the TIF 2.0 procedure to reconstruct the gastroesophageal valve, offering a lower side-effect profile and restoring the anatomy to its natural state. EndoGastric Solutions targets both patients and healthcare providers, aiming to treat a broader population of GERD sufferers.
Notable figures associated with EndoGastric Solutions include its experienced leadership team and a network of investors dedicated to advancing medical technology. The company has achieved significant milestones, including FDA clearance and CE marking for its products, which have been used in thousands of procedures worldwide. EndoGastric Solutions has made a substantial impact by providing a reproducible and standardizable fundoplication method that reduces dependency on daily PPIs and minimizes side effects like gas and bloating.
Companies similar to EndoGastric Solutions include EndoStim, EndoSound, Usgi Medical and EvoEndo.
EndoGastric Solutions was founded in 2003.
EndoGastric Solutions' headquarters is located in Redmond, WA, US.
EndoGastric Solutions' most recent funding round was for $18M (USD) in December 2022.
As of Dec 6, 2022, EndoGastric Solutions has disclosed funding of $380.2M (USD). Undisclosed round amounts are excluded.
EndoGastric Solutions has 92 employees as of Feb 5, 2024.
EvoEndo
evoendo.com
